Thursday, April 10, 2014

Another reason to believe Mannkind shares are overvalued

I already believe Mannkind is overvalued due to it's $2.5 billion market cap, weak balance sheet, and lack of commercial partner.  Now they have another possible inhaled insulin competitor with a planned phase 3 trial next year.  Take a look at Adam's article for the details. 

No comments:

Post a Comment

Thank you for your contribution to BiotechInvestor.com